Manufacturing pre-settings for Stratasys 3D Printers added to latest exocad add-on Model Creator software release to ensure consistent manufacturing quality for production of dental models
Stratasys Ltd. (NASDAQ: SSYS), a manufacturer of 3D printers and materials for personal use, prototyping and production, announced that exocad® GmbH, a global company providing dental CAD/CAM software solutions exclusively for the OEM market, has verified Stratasys 3D Printers for the manufacture of physical dental models in its latest software release.
"We are happy to provide our dental lab customers with the opportunity to use our exocad dental CAD software integrated with Stratasys 3D Printers. This is aimed at enabling them to improve performance and maximize the value of their technological investments," said Tillmann Steinbrecher, General Manager and CEO of exocad GmbH. "exocad means freedom of choice, providing options for integration and customization."
Known for its speedy operation and ease of use, exocad software is fast becoming one of the most popular open CAD software solutions for dental lab technicians. With the exocad validation, customers who run the latest exocad Model Creator software release will have access to Stratasys manufacturing pre-settings to 3D print models. This validation enables a seamless digital dental workflow in which dental labs quickly take intra-oral scans and digitally design and create accurate, smooth dental models on Stratasys 3D Printers.
"As a leading OEM‐branded dental CAD/CAM software, exocad is known for its fast and intuitive operation, allowing dental labs to maximize productivity and minimize training costs," said Avi Cohen, Director of Global Dental, Stratasys. "Fueled by the dental lab industry's ongoing quest for highly flexible, cost‐effective, and 'future‐proof' CAD/CAM solutions and our ongoing commitment to enable a continuous workflow in the clinical setting, we have worked together to create what we believe is the best fitting solution. Together with exocad GmbH, we have designed modules to combine previously disparate workflows to a single, seamless, and easy‐to‐use solution."
For more information visit http://www.StratasysDental.com
Read the exocad White Paper
exocad GmbH ( http://www.exocad.com) is a dynamic and innovative software company committed to expanding the possibilities of digital dentistry and providing OEMs (Original Equipment Manufacturers) with flexible, reliable, and easy‐to‐use CAD/CAM software for dental labs. Founded in 2010 as a spinoff of the world renowned Fraunhofer Organization, by the team that created the Fraunhofer IGD Dental CAD Platform, exocad GmbH has an exclusive license for Fraunhofer's Dental CAD technology, developed by exocad's founders during their research at Fraunhofer IGD. exocad DentalCAD has been chosen by leading OEMs worldwide for integration into their dental CAD/CAM offerings, and tens of thousands of exocad DentalCAD licenses are being sold each year. For more information and a list of exocad reseller partners, please visit http://www.exocad.com.
Stratasys Ltd. (Nasdaq: SSYS), headquartered in Minneapolis, Minn. and Rehovot, Israel, manufactures 3D printers and materials for prototyping and production. The company's patented FDM® and PolyJet™3D Printing technologies produce prototypes and manufactured goods directly from 3D CAD files or other 3D content. Systems include 3D printers for idea development, prototyping and direct digital manufacturing. Stratasys subsidiaries include MakerBot and Solidscape, and the company operates the RedEye digital-manufacturing service. Stratasys has more than 1700 employees, holds over 500 granted or pending additive manufacturing patents globally, and has received more than 20 awards for its technology and leadership. Online at: http://www.stratasys.com or http://blog.stratasys.com
Cautionary Statement Regarding Forward-Looking Statements
Certain information included or incorporated by reference in this press may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements may include, but are not limited to, statements relating to the company's objectives, plans and strategies, statements regarding the company's products and their expected performance, statements that contain projections of results of operations or of financial condition (including, with respect to the MakerBot merger) and all statements (other than statements of historical facts) that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. The company has based these forward-looking statements on assumptions and assessments made by its management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things: the company's ability to efficiently and successfully integrate the operations of Stratasys, Inc. and Objet Ltd. after their merger as well as the ability to successfully integrate MakerBot into Stratasys; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the company operates; projected capital expenditures and liquidity; changes in the company's strategy; government regulations and approvals; changes in customers' budgeting priorities; litigation and regulatory proceedings; and those factors referred to under "Risk Factors", "Information on the Company", "Operating and Financial Review and Prospects", and generally in the company's annual report on Form 20-F for the year ended December 31, 2012 filed with the U.S. Securities and Exchange Commission and in other reports that the Company has filed with the SEC. Readers are urged to carefully review and consider the various disclosures made in the company's SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. Any forward-looking statements in this press release are made as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts for the Public
- USA - +1-877-489-9449
- Europe/Middle East/Africa - +49-7229-7772-0
- Asia Pacific - +852 39448888
Jonathan Wake/Miguel Afonso